EUCTR2020-005732-29-IT进行中（未招募）1 期
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis - N/A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •RANDOMIZED PHASE:
- •1. =18 years of age at the time of consent.
- •2. Diagnosis of MG with generalized muscle weakness meeting the clinical criteria for gMG as defined by the MGFA Clinical Classification Class II a/b, III a/b, or IVa/b at screening.
- •3. MG-ADL score of =6 at screening and baseline.
- •4. Has suboptimal response to current stable therapy for gMG according to the investigator.
- •Stable therapy is defined in the protocol.
- •5. A participant using herbal, naturopathic, traditional Chinese remedies, ayurvedic or nutritional supplements, or medical marijuana is eligible if the use is acceptable to the investigator.
- •6. Participants who have undergone splenectomy must be at least 3 months post resection prior to screening and must be vaccinated as per the United States Center for Disease Control and Prevention annual Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States. (https://www.cdc.gov/vaccines/schedules/hcp/imz/adultconditions html) OR must be vaccinated as per country-specific guidelines or local regulations.
- •7. Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol.
- •8. Is recommended to be up to date on all age-appropriate vaccinations prior to screening as per routine local medical guidelines.
- •9. Man or woman (according to their reproductive organs and functions assigned by chromosomal complement).
- •10. A woman of childbearing potential must have a negative highly sensitive serum at Screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention.
- •11. A woman must be
- •a. Not of childbearing potential
- •b. Of childbearing potential and
- •- Practicing a highly effective, preferably user-independent method of contraception and agrees to remain on a highly effective method while receiving study intervention and until 60 days after last dose. The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention.
- •12. A woman must agree not to donate eggs (ova, oocytes), or freeze for future use for the purposes of assisted reproduction, during the study and for a period of 30 days after the administration of study intervention.
- •13. A male participant who is sexually active with a woman of childbearing potential and who has not had a vasectomy must agree to use a barrier method of birth control (eg, either a condom [with spermicidal foam/gel/film/cream/suppository if available in their locale] or a partner with an occlusive cap [diaphragm or cervical/vault caps] plus spermicidal foam/gel/film/cream/suppository if available in their local), during the study and for at least 90 days after receiving the last administration of study intervention.
- •14. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last administration of study intervention.
- •15. Must sign an ICF indicating that the participant understands the purpose of, and procedures required for, the study and is willing to voluntarily participate in the study and comply with all study procedures.
- •16. Must be able to read and write.
- •Participants who have completed the 24-week double-blind placebo-controlled phase are eligible to enter the OLE phase.
- •Participants who had study intervention discontinued for a reason other than the need for hospitalization or rescue therapy (IVIG, plasmapheresis), and w
排除标准
- •1. Has a history of severe and/or uncontrolled liver, gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension, etc. that, might interfere with the patient’s participation or might jeopardize the safety of the participant.
- •2. Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gMG, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant.
- •3. Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history of MG crisis within 1 month of screening, or fixed weakness (and/or ‘burnt out’ MG).
- •4. Is dependent on gastric tube for nutritional needs or is ventilator-dependent.
- •5. Is actively undergoing radiation or chemotherapy for an unresected thymoma/malignant thymoma.
- •6. Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the study.
- •7. Has current or a history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments.
- •8. Currently has a malignancy or has a history of malignancy within 3 years before screening.
- •9. Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients (refer to the IB).
- •10. Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis to therapeutic proteins (eg, monoclonal antibodies).
- •11. Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening.
- •12. Is planning to father a child while enrolled in this study or donate sperm within 90 days after the last administration of IMP.
- •13. Is currently breastfeeding, pregnant, planning pregnancy, or egg donation during the study or within 30 days after the last dose of IMP.
- •14. History of moderate or severe substance or alcohol use
- •15. Is currently taking IgG Fc-related protein therapeutics, or Fc-conjugated therapeutic agents, including factor or enzyme replacement.
- •16. Has received, rituximab within 6 months prior to first administration of IMP, except for returning Phase 2 participants.
- •17. Has received a live vaccine within 3 months prior to screening or needing live vaccine during the study, or within at least 3 months after the last administration of IMP. Participants are allowed to receive SARS-CoV-2 vaccine, unless it is a live vaccine.
- •18. Has received plasmapheresis, immunoadsorption therapy, or IVIg within 6 weeks prior to baseline.
- •19. Has another medical condition that requires corticosteroids unless the dose has been stable for at least 4 weeks prior to baseline and is expected to remain stable during the study.
- •20. Has another medical condition that requires an immunosuppressive agent unless the medication has been used for at least 6 months, the dose has been stable for at least 3 months prior to baseline and the medication and the dose are expected to remain stable during the study.
- •21. Has previously received nipocalimab. (Not applicable to returning Phase 2 participants)
- •22. Is receiving or has received an investigational intervention (including investigational vaccines) within 3 months or 5 half-lives (whichever is longer) or used an invasive investigational medical device within 3 months before the planned first dose administration of IMP.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to compare the investigational drug EG-1962 with standard of care oral nimodipine in adults with Subarachnoid Hemorrhage caused by a ruptured aneurysm.Aneurysmal subarachnoid hemorrhage (aSAH)MedDRA version: 19.0Level: LLTClassification code 10072200Term: Asymptomatic subarachnoid hemorrhageSystem Organ Class: 100000004852MedDRA version: 19.0Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004852EUCTR2015-005033-53-ATEdge Therapeutics, Inc374
进行中（未招募）
1 期
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia GravisMyasthenia gravis (MG).MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005732-29-DEJanssen-Cilag International N.V.190
进行中（未招募）
1 期
Study to Evaluate the Safety and Effectiveness of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)IgG4-Related DiseaseMedDRA version: 21.0Level: LLTClassification code 10071581Term: IgG4 related sclerosing diseaseSystem Organ Class: 100000004859EUCTR2017-002214-31-ITXencor INC240
进行中（未招募）
1 期
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia GravisMyasthenia gravis (MG).MedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005732-29-DKJanssen-Cilag International N.V.190
进行中（未招募）
1 期
A clinical trial to compare the investigational drug EG-1962 with standard of care oral nimodipine in adults with Subarachnoid Hemorrhage caused by a ruptured aneurysm.Aneurysmal subarachnoid hemorrhage (aSAH)MedDRA version: 20.1Level: LLTClassification code 10072200Term: Asymptomatic subarachnoid hemorrhageSystem Organ Class: 100000004863MedDRA version: 20.1Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004863EUCTR2015-005033-53-DEEdge Therapeutics, Inc282